{"name":"Tae Won Kim","slug":"tae-won-kim","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aatezolizumab plus Bevacizumab","genericName":"Aatezolizumab plus Bevacizumab","slug":"aatezolizumab-plus-bevacizumab","indication":"Hepatocellular carcinoma (Phase 2)","status":"phase_2"}]}],"pipeline":[{"name":"Aatezolizumab plus Bevacizumab","genericName":"Aatezolizumab plus Bevacizumab","slug":"aatezolizumab-plus-bevacizumab","phase":"phase_2","mechanism":"Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.","indications":["Hepatocellular carcinoma (Phase 2)","Advanced or metastatic solid tumors (Phase 2)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE5XNzZjdjdJZHgwSWtaTHVDOFB5WHNzb1JSekg3MVEycDVxTkVIcVZPcDg3dm11X0ltS29tbkJHQTNHeXVNNFlyeGNsZw?oc=5","date":"2026-04-08","type":"pipeline","source":"매일경제","summary":"Gyeongsang Pharmaceutical announced on the 8th that it held an award ceremony for the certificate of.. - 매일경제","headline":"Gyeongsang Pharmaceutical announced on the 8th that it held an award ceremony for the certificate of.. - 매일경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9RclV3U1VhMDNMZHlKa3h0THJjUVlGR3E1emhiaUxJOFJXQmo0T2ZvTDN2TVVLMGM5MlRucDR1UWU1SDBpQzFKWXIzUjdsQldaMElnc3A1Y3pJbUM2UUFCMkZsaTVkT1dCYmJ1bnJR0gFyQVVfeXFMTmw2LUJaWUk2QTNCYXE4ZWtxUDZHWUtKbWViVWZsTGNibXFTUDFNM1RnUjEwbTRwWFVQZFVreXpJZ1U2amNNZkJYeWk4R2NJZVg0WU1sS2tuaEVmajR3UGpJdVJtVk5pM1pJOGxsOGQ0ZGt3?oc=5","date":"2026-03-30","type":"pipeline","source":"koreabiomed.com","summary":"Yuhan–Huinno alliance targets US with AI-powered ECG, prediction tools - koreabiomed.com","headline":"Yuhan–Huinno alliance targets US with AI-powered ECG, prediction tools","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE1tcld0T2N3MTFqVG5QMFowYWpVZHNXR0xqaWNzRFdRQlVNaGVSMm1pZnVhX1RCYXFZTWhTV0Q5Tnk0cjN4WDFTM1VIMA?oc=5","date":"2026-03-12","type":"pipeline","source":"매일경제","summary":"The second term of Hanmi Pharmaceutical CEO Park Jae-hyun, who has been at odds with Hanyang Precisi.. - 매일경제","headline":"The second term of Hanmi Pharmaceutical CEO Park Jae-hyun, who has been at odds with Hanyang Precisi.. - 매일경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNLW11WjdSU1Bnd0JybDZUYjRWdnQ1U2p6bGw3VHlJV3ZpU3JZdjdqVTkyTTRFVGloWnd2NlF0QU5PTjZfRmpJZ3ZFQkpGYjJmWGdQLV9DZ2ZPV2ZaTURjX0Y1bnM4OXBGZ2MybnNnVTlvU3lJZ3RhaDFvZG9XaW13Z2RJNDZob1VVVzhPczJ6a3JxRFFtNDRnU2k5U1BVbzlWQnhPZXNtRkRKcElVNUszZ0hMMkY0NVBU0gG-AUFVX3lxTE9KLUdoSTczUkVrUkNwWFZSUHdFbHUwbDVueE1faFp4c0FHc3VrcFVPQzlCcU9CN1pCcUh6eFMyaGtQZnUtdHZiUlg4VGFxRDhGUFVueWY3SElncXl4TjI1VHhwT29iUEZ6RDJrX3ByMjRnUXc4X2N0N1ZFWUh1dXFxLTRiUjNJYV9sRzZQUnRTTGQ2eV8xd3ZsTDZDX19RWXQ0dHlVYnJueERad2VCd3B5RUJ3aUNCRzI5aFlwMFE?oc=5","date":"2026-01-21","type":"pipeline","source":"The Korea Times","summary":"LG CNS expands AI transformation push into pharma, biotech - The Korea Times","headline":"LG CNS expands AI transformation push into pharma, biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPQkVNSjN0NC00dEcxQmk3NENETlNkSU1ERTRvU0VWUE9mV1hldkNVblFVbmlYcEM3SHg2SE9ocW1QVWE2SXgwVEZidzBfM1BqWXRsV3VIcDhlZDR0c01jemhQckVLYlpLN0MyZHFVODRISFJIeUh6WWZvZUlWSndicWN3WmUwdVlM?oc=5","date":"2025-10-30","type":"deal","source":"조선일보","summary":"U.S.-Korea Tariff Deal Cuts Auto Duties, Leaves Semiconductors Unresolved - 조선일보","headline":"U.S.-Korea Tariff Deal Cuts Auto Duties, Leaves Semiconductors Unresolved - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNV1l4YVM4QnVEZ0NWdl9LMG5WdHBNZ1UyY05aUlBWel81dGdabllXSVlheFlpenFKUm5oTDNUMUJPeXNrLTI3MW1OT3ZEdUg2M1U2LVBQYldVZFdaaUx0bF9DUTYxSUVtamxCZ1JQZEUwUFlVdDJXeW5kLWVIcTFzS1J6WWxnbnpoTUJOUFNn?oc=5","date":"2025-10-15","type":"pipeline","source":"조선일보","summary":"Bang Si-hyuk Tops Founders' Stock Value Ranking - 조선일보","headline":"Bang Si-hyuk Tops Founders' Stock Value Ranking - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBWeVlWaWVwNlRmbWVQS2gwSHA1TmNJem1yb05LWHBKempMRnhaNTc1b19JeHQxSTZ2N0dvWXJkdTBqVGJfU1gzRjh0WldScnRSRllqWjV2SWxzN0NZVElF?oc=5","date":"2025-08-01","type":"pipeline","source":"nature.com","summary":"Pharmacokinetic variability of 20(S)-protopanaxadiol-type ginsenosides Rb1, rd, and compound K from Korean red ginseng in experimental rodents | Scientific Reports - nature.com","headline":"Pharmacokinetic variability of 20(S)-protopanaxadiol-type ginsenosides Rb1, rd, and compound K from Korean red ginseng i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE40UXlJekdkQXRqWFRRWTJsZ256czQ3dEtPVkFRbC1jZlkzcTFGMTBPRGZDOWRtWW9iWVVvZ2NacDc3b0JPeHhjb1c0S05HSl9hODVkNkxsMklzQktQYzE5WjZIS01hZlZoODZVdG5n?oc=5","date":"2024-08-30","type":"pipeline","source":"KED Global","summary":"SK Group’s 3rd-generation daughter comes to the fore - KED Global","headline":"SK Group’s 3rd-generation daughter comes to the fore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9MbzdHUm5aaGFibU0zXzVEc2VycDRuSmhLdC0tMmIyajRlNVhzTHpSUXhhMjZiY3dfNVhIZVYtQjFXTDJIaXJGMWtMNEZNLWVtUjRiNGdRRHJqX0ZHYVZ0dVRFN294d3otSlJ6UQ?oc=5","date":"2022-01-12","type":"pipeline","source":"Pharma Voice","summary":"Talent Pool - Pharma Voice","headline":"Talent Pool","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5KN2gzZnYzbXRvRHQ0TWs5V2ZreTJwakJQbEFOcGhHVlA4RzZVM1EzSFNtcFhoWlNvdXJieUIxU0ZNLXNCa1JRXzBDXy0xUFg4MGFOVTFubWI3SjFnRkwxQQ?oc=5","date":"2020-12-02","type":"pipeline","source":"NEJM","summary":"Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer - NEJM","headline":"Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE02SHhtcTV6UTU3VEg0MkFiSWZQbGpiMXJSVzZBWHZldmtYUXNZSzlVZmR4SUJKVEJHU1BsOXptVHZQTjkxZ3RiVTZMUTZOLWhDY1MzZjBxOVc0UFRVVUJyag?oc=5","date":"2020-08-03","type":"pipeline","source":"Pharmaceutical Executive","summary":"Country Report: Korea - Pharmaceutical Executive","headline":"Country Report: Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5IN3FSbURqTXZ5WWk3cW9JMVhXYWJNUFpXUkVGakV6ZVA4UG9rTVMzWGZXLWczRkd6TUlnWXVSeW8za1d2NEFLWEkwQ3NoTUdFVVpBekZrTlB5VGpzRldEeWtCMl8yVDJTdGVGZg?oc=5","date":"2020-05-05","type":"pipeline","source":"Contract Pharma","summary":"CEO Spotlight: Dr. Tae Han Kim - Contract Pharma","headline":"CEO Spotlight: Dr. Tae Han Kim","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}